Using advanced PET/CT imaging to diagnose certain tumors
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
NA · Huashan Hospital · NCT06148220
This study is testing two new imaging agents to see if they can help doctors better diagnose kidney cancer and lymphoma in patients who already have these conditions.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Huashan Hospital (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06148220 on ClinicalTrials.gov |
What this trial studies
This study aims to optimize and evaluate the diagnostic efficacy of two PET/CT imaging agents, [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6, specifically for detecting renal cancer and lymphoma. Participants will undergo imaging to assess the physiological and pathological distribution characteristics of these agents. The study focuses on patients with confirmed diagnoses of renal cancer or lymphoma, utilizing advanced imaging techniques to improve diagnostic accuracy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with confirmed renal cancer or lymphoma.
Not a fit: Patients with severe hepatic or renal insufficiency or those who have recently undergone significant surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of diagnosing kidney cancer and lymphomas, leading to better-targeted treatments.
How similar studies have performed: Other studies utilizing advanced PET/CT imaging techniques have shown promise in improving cancer diagnostics, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Be between 18 and 65 years of age and of either sex. 2. Affected with renal cancer or lymphoma confirmed by puncture or surgical pathology. 3. Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver. 4. Willingness and ability to cooperate with all programs of this study. Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from the study: 1. Severe hepatic and renal insufficiency; 2. Targeted therapy prior to radiotherapy or PET/CT scan. Renal function: serum creatinine less than or equal to the upper limit of the normal range; 3. Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range. 4. History of serious surgery in the last month. 5. Those who have participated in other clinical trials during the same period.
Where this trial is running
Shanghai
- Huashan Hospital — Shanghai, China (RECRUITING)
Study contacts
- Principal investigator: Fang Xie — Huashan Hospital
- Study coordinator: Yihui Guan, MD
- Email: guanyihui@hotmail.com
- Phone: 13764308300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Kidney Cancer, Lymphomas, Positron Emission Tomography